Use of extended half-life factor IX products in the surgical setting: case series from a UK haemophilia centre
By:
References
- Srivastava A, Santagostino E, Dougall A, et al. WFH guidelines for the management of hemophilia, 3rd edition. Haemophilia 2020; 26 Suppl 6: 1–158. doi: 10.1111/hae.14046.
- Mannuci PM. Hemophilia therapy: the future has begun. Haematologica 2020; 105(3): 545–553. doi: 10.3324/haematol.2019-232132.
- Escobar MA, Brewer A, Caviglia H, et al. Recommendations on multidisciplinary management of elective surgery in people with haemophilia. Haemophilia 2018; 24(5): 693–702. doi: 10.1111/hae.13549.
- Pollard D, Harrison C, Dodgson S, Holland M, Khair K. The UK haemophilia specialist nurse: Competencies fit for practice in the 21st century. Haemophilia 2020; 26(4): 622–630. doi: 10.1111/hae.14002.
- Ragni MV, Pasi KJ, White GC, Giangrande PL, Courter SG, Tubridy KL; Recombinant FIX Surgical Study Group. Use of recombinant factor IX in subjects with haemophilia B undergoing surgery. Haemophilia 2002; 8(2): 91–7. doi: 10.1046/j.1365-2516.2002.00587.x.
- Ar MC, Balkan C, Kavaklı K. Extended half-life coagulation factors: a new era in the management of hemophilia patients. Turk J Haematol 2019; 36(3): 141–154. doi: 10.4274/tjh.galenos.2019.2018.0393.
- Roth DA, Kessler CM, Pasi KJ, et al. Human recombinant factor IX: safety and efficacy studies in hemophilia B patients previously treated with plasma-derived factor IX concentrates. Blood 2001; 98: 3600–3606. doi: 10.1182/blood.v98.13.3600.
- Shapiro AD, Di Paola J, Cohen A, et al. The safety and efficacy of recombinant human blood coagulation factor IX in previously untreated patients with severe or moderately severe hemophilia B. Blood 2005; 105: 518–525. doi: 10.1182/blood-2004-06-2283.
- Windyga J, Timofeeva M, Stasyshyn O, et al. Phase 3 clinical trial: perioperative use of nonacog gamma, a recombinant factor IX, in previously treated patients with moderate/severe hemophilia B. Clin Applied Thromb Haemost 2020; 26: 1–10. doi: 10.1177/1076029620946839.
- Chowdary P, Holmström M, Mahlangu JN, et al. Managing surgery in hemophilia with recombinant factor VIII Fc and factor IX Fc: Data on safety and effectiveness from phase 3 pivotal studies. Res Pract Thromb Haemost 2022; 6: e12760. doi: 10.1002/rth2.1276d.
- Castaman G, Matino D. Hemophilia A and B: molecular and clinical similarities and differences. Haematologica 2019; 104(9): 1702–1702. doi: 10.3324/haematol.2019.221093.
- Curtin J, Santagostino E, Karim FA, et al. Simplifying surgery in haemophilia B: Low factor IX consumption and infrequent infusions in surgical procedures with rIX-FP. Thromb Res 2020; 188: 85–9. doi: 10.1016/j.thromres.2020.02.011.
- Négrier C, Abdul Karim F, Lepatan LM, et al. Efficacy and safety of long-acting recombinant fusion protein linking factor IX with albumin in haemophilia B patients undergoing surgery. Haemophilia 2016; 22(4): e259–66. doi: 10.1111/hae.12972.
- Loveday HP, Wilson JA, Pratt RJ, et al. epic3: national evidence-based guidelines for preventing healthcare-associated infections in NHS hospitals in England. J Hosp Infect 2014; 86 Suppl 1: S1–70. doi: 10.1016/S0195-6701(13)60012-2.
- Mulders G, Uitslager N, Kavanagh M, et al. The role of the specialist nurse in comprehensive care for. Bleeding disorders in Europe: An integrative review. Haemophilia 2024; 30(3): 598–608. doi: 10.1111/hae.14974
DOI: https://doi.org/10.2478/jhp-2025-0012 | Journal eISSN: 2055-3390
Language: English
Page range: 96 - 103
Published on: Sep 16, 2025
Published by: Haemnet Ltd
In partnership with: Paradigm Publishing Services
Publication frequency: 1 times per year
Keywords:
Related subjects:
© 2025 Molly Ndebele, Emma Charnick, Nawal Asir, Elsa Aradom, published by Haemnet Ltd
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.